Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 6Recruiting 5Unknown 4Not yet recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Neoplasms 5Stomach Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Advanced Solid Tumors 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thoracic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × Injections × Clear all
NCT04714190 2023-12-21

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

RemeGen Co., Ltd.

Phase 3 Unknown
351 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05720598 2023-02-09

POLA

Medical University of Lublin

Phase NA Unknown
190 enrolled
Gastrointestinal

Lymphatic Metastasis, Stomach Neoplasms

NCT05009966 2021-10-25

Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Unknown
272 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04345783 2020-04-14

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Beijing Friendship Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡